Scopolamine is a naturally occurring tropane alkaloid which acts as a muscarinic antagonist. It is commonly used to treat motion sickness and postoperative nausea. By blocking the activation of muscarinic acetylcholine receptors in the central nervous system, scopolamine helps reduce nausea and vomiting. It is available in various forms such as transdermal patches, gels, tablets and injections. The non-invasive transdermal delivery system helps ensure steady absorption of the drug into systemic circulation. Growing demand for effective treatment of nausea, especially from cancer patients undergoing chemotherapy and women suffering from morning sickness, has been a key driver of the scopolamine market.
The global scopolamine market is estimated to be valued at US$ 3,676.85 billion in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The rising prevalence of anxiety disorders has opened new growth prospects for scopolamine. Studies have shown that scopolamine can act as an effective anxiolytic by blocking cholinergic transmission in the amygdala and hippocampus regions of the brain. The non-sedating property of scopolamine makes it more suitable for anxiety patients who need to remain alert. Development of newer formulations targeting anxiety symptoms can unlock new revenue streams for companies in this market. Low dosing options of scopolamine in combination with other anxiolytics hold promise for the treatment of mild to moderate anxiety conditions. Further research on the anxiolytic effects is likely to boost adoption of scopolamine thereby propelling the market growth over the forecast period.
Porter's Analysis
Threat of new entrants: The scopolamine market requires high capital investments for R&D and production facilities which limits threat of new entrants.
Bargaining power of buyers: Large pharmaceutical buyers have significant bargaining power over suppliers due to the fragmented nature of suppliers in the market.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to availability of substitute resources and players in the market.
Threat of new substitutes: Threat of substitutes is low as scopolamine provides unique benefits for treatment of motion sickness.
Competitive rivalry: The scopolamine market is highly competitive with presence of numerous global and regional players.
SWOT Analysis
Strengths: Strong R&D capabilities and robust product pipelines of major players. Weaknesses: Presence of alternative treatment options and side effects associated with scopolamine drugs.
Opportunities: Increasing geriatric population suffering from Parkinson's disease and motion sickness. Untapped growth potential in emerging markets.
Threats: Stringent regulatory requirements and drug approval processes. Price erosion due to patent expiries of blockbuster drugs.
Key Takeaways
The Global Scopolamine Market Demand is expected to witness high growth over the forecast period owing to increasing prevalence of motion sickness. The global Scopolamine Market is estimated to be valued at US$ 3676.85 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
North America dominates the scopolamine market led by the US driven by well-established healthcare system and growing geriatric population suffering from neurological disorders. Europe stands as the second largest region with major markets including Germany, UK and France contributing significantly to regional growth.
Key players operating in the scopolamine market are Baxter International Inc., GlaxoSmithKline plc, Novartis AG, Perrigo Company plc, Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation. The market is highly competitive in nature due to presence of global established players and large number of generic manufacturers. Key players focus on product innovation and expanding geographically through strategic collaborations to strengthen their market position.
Get more insights on this topic: https://www.ukwebwire.com/scopolamine-market-trends-size-and-share-analysis/
The Scopolamine market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the scopolamine market include Alchem International, Alkaloids of Australia, Baxter International Inc., Caleb Pharmaceuticals, Inc., Centroflora-Cms, Fine Chemicals Corporation, GlaxoSmithKline plc., Myungmoon Pharma Co. LTD., Novartis AG, Perrigo Company plc.
An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Scopolamine Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/scopolamine-market/download-sampleMarket DynamicsAn increasing number of domestic and international travelers undergoing motion sickness is driving the market growth.
Also, growing nmber of surgeries leading into rise in demand of product to control postoperative nausea and hyper salivary secretion is again pushing the market growth uphill.
However, stringent regulation on production in various regions is likely to hinder the market growth.This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis.
